BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210225
DTSTAMP:20260515T025617
CREATED:20201111T111102Z
LAST-MODIFIED:20201111T111102Z
UID:27878-1613952000-1614211199@www.pharmajournalist.com
SUMMARY:Operationalize: Expanded Access Programs
DESCRIPTION:Overcome the Operational Hurdles Preventing You From Bringing Treatments to Patients in Need: Say Goodbye to the Worry and Uncertainty of Setting Up and Managing an Expanded Access Program. \n \nBy bringing together the world’s leading thinkers in Expanded Access Programs\, this exclusive platform will clarify the complex issues through end-to-end Expanded Access Program Operationalization. Through open discussion\, sharing best-practice case studies\, and removing hypotheticals: this event provides an unrivalled opportunity to solve your challenges across the entire program timeline. \nOver the course of 3 interactive days\, 20 expert speakers will share their insights on program set-up\, US and EU regulatory pathways\, product supply\, data collection\, using technology to streamline processes and patient communication\, closing out programs and moving to commercialization. So\, next February\, join your peers from across the value chain to develop your own toolkit of solutions from the only case study led\, operationally–focused access programs event. \nTo know more about Operationalize: Expanded Access Programs please click here.
URL:https://www.pharmajournalist.com/event/operationalize-expanded-access-programs/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:nfo@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210222
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T025617
CREATED:20210114T085910Z
LAST-MODIFIED:20210122T141443Z
UID:28470-1613952000-1614124799@www.pharmajournalist.com
SUMMARY:Animal Health Innovation Europe
DESCRIPTION:The 6th Annual Animal Health Innovation Europe taking place on the 22-23rd February 2021 will showcase the most exciting innovations in animal health and nutrition\, connecting those businesses with financial investors and strategic corporate partners\, making it the sector’s premier investment forum in Europe. \n \nJoin us to hear investment pitches\, network with C-Suite Executives and learn from CEO-level panel discussions that address the trends and market dynamics of the animal health industry\, across all species. This year’s virtual format gives us a unique opportunity with our programming to involve a wider array of stakeholders and key participants in the value chain so we can address the full scope of how animal health impacts pet owners\, veterinarians\, and farmers today. We have advanced our networking capabilities to help you recreate the unexpected business interactions that are so valuable at our face-to-face events\, through virtual roundtable discussions\, workshop groups and interactive content delivery. \nFeaturing speakers from industry leaders such as Elanco\, Zoetis\, Phibro\, and many more\, 2021 content will cover expanded insights on: sustainability and efficiency in the protein supply chain\, the accelerated use of digital solutions in the pet sector\, how the animal health industry will continue to generate value through the Covid-19 pandemic\, and new approaches to stimulate technology adoption and enhance the productivity of European farmers. \nJoin us for the innovation showcase\, a feature of the event that is a unique opportunity for emerging companies with amazing technology to present in front of the industry’s most influential figures and investors. Split between companion and production animal sectors\, 20 start-ups\, hand-picked by the Selection Committee (who all have an extensive breadth of experience and knowledge across animal health and nutrition industries)\, introduce themselves and their innovations and achievements on the main stage. \nBook now to join us in shaping the future of animal health.
URL:https://www.pharmajournalist.com/event/animal-health-innovation-europe/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210224
DTSTAMP:20260515T025617
CREATED:20200525T084418Z
LAST-MODIFIED:20201123T135747Z
UID:25675-1614038400-1614124799@www.pharmajournalist.com
SUMMARY:Purify'20
DESCRIPTION:PURIFY – Chromatography Purification Conclave \nPURIFY Conclaves are pioneers of dedicated conferences in India that will help stretch possibilities\, be it discovery\, development or scaleups! \nThe pharmaceutical industry continues to dwell deeper into the growing possibilities for chromatography purification; the PURIFY conclaves touches upon diverse aspects of chromatography purification. \n \nThe attendees at PURIFY get exposed to a myriad of topics that could change the way they work…change the way they purify. New separation techniques and approaches\, niche topics\, deeper understanding of preparative and process chromatography and allied fields\, and upcoming application areas that will provide quality substance to the discerning scientists. So\, if you wish to get that additional gram\, which is purer\, in as less a time\, with minimal resources…there will surely be something for you at PURIFY conclaves! \nThe annually occurring PURIFY Conclave is an initiative by Custage Marketing Solutions LLP\, a Mumbai based company. \nThe PURIFY conclave is attended by analytical and research chemists\, scientists with scale-up and process development knowledge\, managers\, group heads\, natural product purification experts\, experts from quality and manufacturing\, academicians\, policy makers\, supply chain heads etc. of this pharmaceutical – APIs\, peptides\, proteins\, oligonucleotides\, chiral molecules\, bio-pharmaceutical\, fine chemicals\, environmental studies\, food and beverage\, polymers\, biotechnology\, cosmetics and fragrance to understand the advancements in chromatography platforms. \nThe maiden PURIFY’19 edition was a huge hit amongst fellow chromatographers\, steered by our esteemed advisory board. (For more details please visit: https://www.linkedin.com/showcase/purifyconclave/) PURIFY’19 was attended by 113 delegates across 19 cities\, spread across 51 corporates with 14 speakers and 6 display zones! \nThe knowledge comes to you from dignitaries who are institutions on their own in chromatography purification and related. \nLooking forward to seeing you at PURIFY’20!\nV: ITC Kohenur\, Hyderabad\nD: 23 February\, 2021\nTo book your seats please call Rashi: +91-91366 00573
URL:https://www.pharmajournalist.com/event/purify20/
LOCATION:ITC Kohenur\, Hyderabad\, India
ORGANIZER;CN="Custage Marketing Solutions LLP":MAILTO:rashi@custage.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T025617
CREATED:20201109T080924Z
LAST-MODIFIED:20201109T081324Z
UID:27836-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:RAS – Targeted Drug Discovery – Digital Summit
DESCRIPTION:Recent clinical advancements of KRAS G12C inhibitors have generated increased interest in the fight to bring an end to RAS driven cancers. However\, their specificity to only target G12C mutations\, leaves huge untapped therapeutic potential to target all RAS driven cancers beyond the lungs. This calls for continued research efforts by industry and academic experts alike. \n \nThe Digital RAS- Targeted Drug Discovery Summit is the premium forum for cellular\, preclinical and translational RAS experts to explore potential strategies to tackle undrugged RAS oncogenes beyond KRAS G12C. \nAs part of our industry leading and dedicated RAS conference series\, this exciting next iteration is shining the spotlight on: \n§     Identifying key learnings from known pre-clinical and clinical data for viable KRAS direct inhibitors to effectively drug all RAS isoforms \n§     Exploring G12C pre-clinical and clinical data to optimise future RAS targeting strategies \n§     Learning from the patterns of RAS mutations to understand prognostic or predictive power in various cancer types beyond lung cancer \nJoin senior experts from leading biotech\, large pharma and pioneering academic institutions at the Digital RAS- Targeted Drug Discovery Summit as they identify future models and strategies for streamlining anti-RAS therapeutics into the clinic. \nTo know more about RAS – Targeted Drug Discovery please click here.
URL:https://www.pharmajournalist.com/event/ras-targeted-drug-discovery-digital-summit/
LOCATION:Digital Event\, GMT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210223
DTEND;VALUE=DATE:20210226
DTSTAMP:20260515T025617
CREATED:20201111T111739Z
LAST-MODIFIED:20201111T111739Z
UID:27882-1614038400-1614297599@www.pharmajournalist.com
SUMMARY:9th Neurodegenerative Drug Development Summit
DESCRIPTION:The 9th Neurodegenerative Drug Development Summit is the industry’s definitive and unrivalled forum focused on revealing hot and promising pockets of innovation in drug discovery for neurodegenerative diseases and combating translational challenges by shining a light on pioneering companies leading the way to meet this dire medical need. \n \nBuilding on the success of last year’s meeting\, this year’s program showcases new biotechs trailblazing this space and will put the spotlight on the latest scientific advances in terms of diverse targets\, novel modalities and innovative trial design. Across 3 action-packed\, case-study driven days and 2 parallel tracks of learning\, we present the opportunity to join us online in 2021 to overcome technical and operational challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit. \nWhether you are working in a team dedicated to Parkinson’s\, Alzheimer’s\, ALS\, Frontotemporal Dementia or a rare neurodegenerative disorder\, join this intimate\, industry-led forum to not only to learn from those spearheading this space\, but to network and build meaningful partnerships with over 180 neurodegenerative drug development experts. \nTo know more about 9th Neurodegenerative Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/9th-neurodegenerative-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210309
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T025617
CREATED:20201022T103840Z
LAST-MODIFIED:20201022T104916Z
UID:27595-1615248000-1615507199@www.pharmajournalist.com
SUMMARY:Gene Therapy for Blood Disorders 2021
DESCRIPTION:2020 has been an exciting year for Gene Therapies targeting Blood Disorders. Despite FDA’s recent rejection of BioMarin’s hemophilia gene therapy program\, the clinical landscape is progressing quickly with Pfizer and Sangamo kicking off their phase 3 and bluebird bio receiving European approval for their beta-thalassemia candidate. With pipelines advancing and emerging companies joining the blood disorders field\, it is essential for gene therapy developers to communicate and share lessons learned to accelerate their programs to market. \n \nThe 2nd Gene Therapy for Blood Disorders meeting is taking place in March 2021\, focusing on the clinical and commercial challenges of developing gene therapies targeting hemophilia\, sickle cell disease and beta thalassemia. Evaluate the best strategies for a commercial launch in blood disease and optimize your trial design to ultimately transform your clinical candidates into a commercial reality. \nTo know more about Gene Therapy for Blood Disorders please click here.
URL:https://www.pharmajournalist.com/event/gene-therapy-for-blood-disorders-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210313
DTSTAMP:20260515T025617
CREATED:20210226T095658Z
LAST-MODIFIED:20210226T100244Z
UID:29127-1615420800-1615593599@www.pharmajournalist.com
SUMMARY:2nd Annual MarketsandMarkets Infectious Disease Diagnostics and Point-Of-Care Testing Virtual Conference
DESCRIPTION:The Diagnostics sector has emerged as a prominent game changer in healthcare\, because of many technological advancements taking place within the field. As diagnostics is a key for making the treatment decisions\, it needs to be quicker\, précised\, and accurate. \nPoint-of-care testing (POCT) is a growing testing. Today\, you may see POCT in a hospital with handheld gadgets or small testers in emergency department\, extensive care setting\, popular clinical wards\, and imaging facilities. And market analyses that the world is moving from critical laboratory testing to testing for quick and accurate results at the patient’s point of care. \n \nIn the era of improved diagnostics\, our 2nd Annual Virtual Event on Infectious Disease Diagnostics and Point-Of-Care Testing will serve as a networking place for Diagnostics professional\, Industrial specialists\, and solution providers to address the rising innovation in its discipline and the way it can be used as disease prevention tool. \nEvent Website: https://bit.ly/3gNnkOq \nRegistration link: https://bit.ly/3oRX7kH
URL:https://www.pharmajournalist.com/event/2nd-annual-marketsandmarkets-infectious-disease-diagnostics-and-point-of-care-testing-virtual-conference/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210311
DTEND;VALUE=DATE:20210312
DTSTAMP:20260515T025617
CREATED:20210226T105316Z
LAST-MODIFIED:20210226T111537Z
UID:29175-1615420800-1615507199@www.pharmajournalist.com
SUMMARY:MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT (Time Zone - 9AM EST)
DESCRIPTION:High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’s Crystal Ball event \nThe end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy\, Gene Therapy\, Monoclonal Antibodies\, Vaccines\, biosimilars and biobetters\, plasma therapy as well as others. \nA host of attractive\, high growth opportunities such as single use systems\, Lab Scale and CGMP manufacturing and R&D\, Crispr and other Gene editing tools and technologies\, Novel downstream bioprocessing methods etc could be pursued. Participants such as CROs\, CMOs\, Bioprocess solutions manufacturers\, Biobanks\, automation technology providers etc can benefit from this unprecedented growth over the next 5 years. \nThis Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem\, as seen through the lens of eminent CXOs in this space \nEvent Website: https://bit.ly/3qJYdQF  \nRegistration link: https://bit.ly/2Mcpg8i 
URL:https://www.pharmajournalist.com/event/marketsandmarkets-biopharma-manufacturing-crystal-ball-event-time-zone-9am-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210318
DTSTAMP:20260515T025617
CREATED:20201214T152316Z
LAST-MODIFIED:20201214T152538Z
UID:28302-1615766400-1616025599@www.pharmajournalist.com
SUMMARY:Targeting RNA Congress 2021
DESCRIPTION:Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins\, therefore making it an obvious target. With Risdiplam being approved by the FDA in August\, and several major collaborations also being penned throughout 2020\, including a $190 million deal between Arrakis and Roche\, it seems like a good time to target these protein precursors. \n \nThe Targeting RNA Congress will return for 2021\, March 15-17\, and will take a look at the latest techniques to analyse and predict protein structure\, as well as hearing from leading researchers and industry on how to incorporate learnings from RNA biology into potent and selective ligands to help prevent\, rather than treat\, disease. \nKey Outcomes from the summit include: \n\nLearn where to target your RNA molecules after exploring the newest biophysical techniques to analyse RNA structure\, including NMR\, Cryo-EM\, and in silico modelling with Silvi Rouskin\, (MIT)\, Wah Chiu (Stanford University) and Hashim Al Hashimi (Duke University).\nUnderstand what makes a druggable RNA target and hear from expert RNA biologists to advise how best to drug your favourite RNA targets with Anima Biotech and Craig Blain (Arrakis).\nGet translational insights into what considerations are important when creating a small molecule that targets RNA by learning how to develop tools for assessment of RNA targets with Amanda Garner (University of Michigan)\nHear what new techniques can help to drug these tricky targets\, including RNAi\, RNA degraders and RIBOTACs with Gene Yeo (UCSD)\, Jonathan Hall (Zurich) and Matt Disney (Scripps and Expansion).\n\nTo know more about Targeting RNA Congress please click here.
URL:https://www.pharmajournalist.com/event/targeting-rna-congress-2021/
LOCATION:Virtual Summit EST Timezone
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210315
DTEND;VALUE=DATE:20210317
DTSTAMP:20260515T025617
CREATED:20201223T083652Z
LAST-MODIFIED:20201223T083652Z
UID:28371-1615766400-1615939199@www.pharmajournalist.com
SUMMARY:SMi’s 2nd Annual AI in Drug Discovery
DESCRIPTION:Chaired by: Darren Green\, Director of Molecular Design & Senior Fellow\, GSK \nSponsored by: OpenEye Scientific Software \nExploring the latest Innovations in Machine Learning for Enhancing Discovery Pipelines \nSMi is proud to present its 2nd Annual AI in Drug Discovery Conference\, taking place on the 15-16 March 2021. \nWith the global Artificial Intelligence (AI) in Drug Discovery Market size expected to exceed $3\,900 million by 2027\, the conference agenda will encompass key drivers leading the way into a shorter\, cheaper\, and more successful R&D era. The conference will be a particular focus on case studies from leading pharma and biotech\, as well as a close-up view on the paradigm shift from undruggable targets to ‘challenging to drug’. \n \nFurthermore the event will focus on 4 key themes: machine learning and automation for improved drug discovery pipelines; effective prediction of compound properties; data robustness and curation; innovative use of AI for rare and undruggable diseases\, and will highlight key case studies across these themes\, uncovering key developments in pharma of data optimization and to aid therapeutic discovery. Real-world examples of AI in structure-based drug design and patient relevant data will be explored in eye-opening detail \nEvent Hashtag: #SMiAIDrugDis \nHIGHLIGHTS FOR 2021 INCLUDE: \n\nDiscover the latest innovations in AI-based drug discovery platforms\nEngage in case study presentations from leading pharma and biotech companies on machine learning and improved drug discovery pipelines\nUnderstand how AI can be effectively implemented to enhance productivity\nDelve into best practices in data quality\, curation\, and validation\nExplore how AI is being used to unlock therapies that have evaded traditional drug discovery\n\nKEY SPEAKERS INCLUDE \n\nNoor Shaker\, CEO\, Glamorous AI\nMaria Luisa Pineda\, Co-Founder & CEO\, Envisagenics\nEd Addison\, Co-founder\, Chairman\, and CEO\, Cloud Pharmaceuticals\nLiling Warren\, Director\, Head of Translational Medicine Statistics\, Teva Pharmaceuticals\nLili Peng\, Associate Director Scientific Ecosystem Analytics Lead\, Biogen\nMark De Pristo\, CEO\, BigHat Biosciences\nPhilipe Moingeon\, Head of Immuno-inflammation\, Servier\nHugo Ceulemans\, Scientific Director\, Discovery Data Sciences\, Janssen\nPeter Henstock\, Machine Learning & AI Lead\, Pfizer\nNaheed Kurji\, CEO\, Cyclica\n\nWHO SHOULD ATTEND \nCEOs\, Presidents\, Vice Presidents and Global Heads\, Executive Directors\, Vice President & Global head\, Principal Scientists\, Heads of Business Development\, Directors of Pharma/Biotech firms.
URL:https://www.pharmajournalist.com/event/smis-2nd-annual-ai-in-drug-discovery/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210322
DTEND;VALUE=DATE:20210324
DTSTAMP:20260515T025617
CREATED:20201028T124553Z
LAST-MODIFIED:20201028T124553Z
UID:27686-1616371200-1616543999@www.pharmajournalist.com
SUMMARY:Parallel Trade 2021 – Virtual conference: online access only
DESCRIPTION:Exploring the challenges\, practices and drivers in the aftermath of the transition for Parallel Trade \nSMi present’s its 15th annual Parallel Trade virtual conference\, taking place virtually on the 22nd and the 23rd March 2021. As the only parallel trade conference in Europe\, this event provides the perfect platform for industry experts from both sides of the coin to come together and share perspectives on the practice of parallel trade. \n\nThe 2021 event will be more significant than ever before due to the transition period after Brexit coming to an end this year. As such\, the UK will no longer be part of the EU free market. This will mean increased medicines prices\, reduced access to some specialist drugs and greater risk of supply chain shortages. In a post-Brexit environment\, exhaustion of rights will cease to apply to the UK\, making import and export a costly business and in a worst-case scenario could effectively kill parallel distribution. \nThis conference will bring together industry experts to discuss the challenges and drivers of the industry\, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive). The conference will also provide global insights on Parallel trade and will reflect on key takeaways for other member states. \nRegister online for only £999: www.parallel-trade.com/pjwl    \nThe benefits of attending: \nLearn new perspectives and case studies through presentation\, panel discussions and interactive workshops from industry KOLs. Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market. Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices. Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices. Discover what the industry has learnt from COVID-19 and the impact on export bans. \nPlus\, one post-conference interactive workshop \nWorkshop: The law of parallel trade: past\, present and future\nWorkshop Leaders:\nChristopher Stothers\, Partner\, Bruckhaus Freshfields Deringer\nSharon Malhi\, Senior Associate\, Antitrust\, Competition and Trade\, Bruckhaus Freshfields Deringer \n Who should attend: \nVice President/ Heads of/General Managers: \n\nInternational Trade and Relations\nSupply Chain Development – Brexit\nBrexit Implementation\nMarket Access\nSupply Chain Manager\nParallel trade reporting\nRegulatory Affairs\nIP\nPurchasing\nPolicy Patent Operations\nEuropean Affairs\nSupply and Demand\nAttorney\nDistribution\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nLinkedIn: @SMi Pharma\nTwitter: @SMiPharm #SMi #SMiParallel
URL:https://www.pharmajournalist.com/event/parallel-trade-2021-virtual-conference-online-access-only/
LOCATION:Virtual Event
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T025617
CREATED:20210119T095042Z
LAST-MODIFIED:20210119T095042Z
UID:28574-1616457600-1616716799@www.pharmajournalist.com
SUMMARY:FcRn-Targeted Therapies for Autoimmune Disorders Summit
DESCRIPTION:The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis\, half-life extension\, and recycling of human serum albumin and IgG\, however in the case of more than 100+ rare and autoimmune disorders\, this can not only be detrimental\, but lethal to the health of the individual. Following the high profile J&J-Momenta deal\, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020\, other large players are poised to bring their candidates through the clinic in rapid succession. \n \nThe digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first\, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. \nThe 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. \nJoin 100+ experts online from companies such as CSL Behring\, Eli Lilly\, Roche\, Momenta\, Alexion\, Argenx and more to discuss FcRn MOA\, preclinical model selection and translation\, high throughput assays for ligand screening\, IgG engineering\, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.
URL:https://www.pharmajournalist.com/event/fcrn-targeted-therapies-for-autoimmune-disorders-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260515T025617
CREATED:20210226T101236Z
LAST-MODIFIED:20210226T101236Z
UID:29150-1616457600-1616630399@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
DESCRIPTION:One of the major challenges faced by the players in this market\, especially CMOs that offer HPAPI manufacturing services\, is the continual evolution of industry standards\, technologies\, and regulations. \nOwing to their target release characteristics\, HPAPIs find major applications in target therapies for cancer. Globally\, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases\, glaucoma\, and specifically cancer have a significant impact on the health status of people worldwide\, with comparatively higher growth rates in developing countries. \nThe 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards\, technologies\, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations\, live case studies and breakthrough panel discussions. \nEvent Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register  
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference-cet-time-zone/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T025617
CREATED:20201119T113716Z
LAST-MODIFIED:20201119T113716Z
UID:27982-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit
DESCRIPTION:Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment \nThe renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs\, not only as single agents\, but also in combination with other immunomodulatory drugs. \n \nTherapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor\, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state\, acting as a complementary strategy to a suite of cancer immunotherapies approaches. \nThe virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients. \nJoin us and leading experts from Roche\, CytomX\, Philogen\, Bristol-Myers Squibb\, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose\, determining the mechanisms of action and hear the latest data coming out of the clinic. \nTo know more about Cytokine-Based Cancer Immunotherapies Summit please click here.
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T025617
CREATED:20210114T091620Z
LAST-MODIFIED:20210122T141247Z
UID:28478-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Animal Microbiome Congress
DESCRIPTION:The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat\, aquaculture\, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events\, we have built an international animal microbiome community of 600+ people from 30+ countries. \n \nThrough comprehensive industry-academic discussion panels\, engaging keynotes\, interactive roundtables\, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals\, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format\, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters\, Deep Dive Roundtable groups of 9 people working together to tackle industry issues\, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically. \nJoin us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture\, production\, and companion animals\, improving health outcomes for production and companion animals\, reducing the cost of animal ownership and making farming more sustainable\, and translating academic research into commercial products whilst steering through challenging regulatory hurdles. \nBook now to join us in unlocking the full functional potential of the Animal Microbiome.
URL:https://www.pharmajournalist.com/event/animal-microbiome/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210327
DTSTAMP:20260515T025617
CREATED:20210226T115030Z
LAST-MODIFIED:20210226T115030Z
UID:29181-1616544000-1616803199@www.pharmajournalist.com
SUMMARY:8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
DESCRIPTION:The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 – 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. \nRegarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \nEvent Website https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-time-zone-central-european-time-cet/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210325
DTEND;VALUE=DATE:20210327
DTSTAMP:20260515T025617
CREATED:20210226T103615Z
LAST-MODIFIED:20210226T103615Z
UID:29166-1616630400-1616803199@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets Infection Control\, Sterilization & Decontamination Virtual Conference (GMT)
DESCRIPTION:Based on the survey on 1\,000 hospitals in 33 countries\, European Centre for Disease Prevention and Control (ECDC) estimates that that on any given day\, one in 18 patients in a European hospital has healthcare-associated infection (HAIs). Most the countries (26 out of 33) reported the major three types of HAIs: pneumonia and lower respiratory tract infection\, surgical site infection and urinary tract infection. \nThe estimated number of patients in UK acquiring HAIs is approx. 300\,000 a year\, according to a report by National Institute for Health and Care Excellence (NICE). It costs the NHS approximately £1 billion a year\, and £56 million of this is estimated to be incurred after patients are discharged from hospital. NHS has now adopted no-tolerance policy towards spread of HAIs. \nMarketsandMarkets is organizing 5th Annual Infection Control\, Sterilization and Decontamination in Healthcare Virtual Conference\, scheduled for 25th & 26th March 2021\, aiming at providing platform to experts from hospitals\, academia\, and government institutions discussing the innovations\, challenges\, and future aspects of infection control\, decontamination\, and sterilization. \nEvent Website: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference/register
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-infection-control-sterilization-decontamination-virtual-conference-gmt/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:aradhna.robert@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210329
DTEND;VALUE=DATE:20210401
DTSTAMP:20260515T025617
CREATED:20210208T084530Z
LAST-MODIFIED:20210208T084530Z
UID:28854-1616976000-1617235199@www.pharmajournalist.com
SUMMARY:LEAP HR: Life Sciences Spring Edition
DESCRIPTION:LEAP HR: Life Sciences Spring Edition is your best opportunity to uncover the radical strategies biopharma people leaders are putting in place to ensure they are a flexible employer of choice in a competitive industry. \nThis unique forum is shining a light on how the boldest life sciences HR leaders are rethinking the HR function and redefining the workforce of the future in order to continue to innovate and thrive in the face of change. \nStep inside the HR innovation that is making a difference to employees\, patients and customers – and leave with a brand new playbook for the people function to thrive in a post-vaccine world. \nTo know more about LEAP HR: Life Sciences Spring Edition please click here.
URL:https://www.pharmajournalist.com/event/leap-hr-life-sciences-spring-edition/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@leap-hr.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210330
DTEND;VALUE=DATE:20210402
DTSTAMP:20260515T025617
CREATED:20201202T152441Z
LAST-MODIFIED:20201202T152747Z
UID:28146-1617062400-1617321599@www.pharmajournalist.com
SUMMARY:Gene Therapy Comparability
DESCRIPTION:The inaugural Gene Therapy Comparability Summit is the only industry dedicated meeting to ensuring your manufacturing processes are effective and comparable at every stage of development\, supporting a seamless transition to the larger scales required for commercialization. \nThis meeting will unite large pharma and innovative biotechs including Pfizer\, Biogen\, BioMarin and Takeda as they share best practices\, lessons learned and analytical data across the comparability lifecycle. \n \nFocused specifically on enhancing your gene therapy comparability approach\, join us to ensure you maintain safety\, quality\, consistency and efficacy throughout scale-up from clinical to commercial-scale manufacturing\, and satisfy regulatory demands to avoid costly delays to clinical programs. \nIncorporating insights from leading CMC\, Regulatory\, Analytical and Process Development experts\, this is your opportunity to gain extensive technical information on challenges like ensuring manufacturing processes are comparable when changing facilities and cell lines\, developing effective bioassays for use in comparability studies and handling the limited gene therapy lots available. \nJoin your peers online and discover: \n\nHow Biogen defined a robust comparability strategy for late phase gene therapy products\nGain insights into the planning and considerations for a comparability study and risk assessment and understand what defines process comparability vs analytical comparability with Amicus Therapeutics\nHear from the National Institute of Biology and discover if results of non-related analytical methods can be directly compared\nLearn from the Italian Medical Agency and take a deep dive into regulatory expectations for ATMP comparability and comparability exercises\nExplore next generation sequencing (NGS) and how its application can be utilized for comprehensive rAAV genome characterization with Biogen\nBetter understand the challenges associated with limited batch retention and sample availability in the context of comparability and learn best practices for mitigating such challenges with Gyroscope Therapeutics\n\nView the full event guide to find out more!
URL:https://www.pharmajournalist.com/event/gene-therapy-comparability/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210407
DTEND;VALUE=DATE:20210410
DTSTAMP:20260515T025617
CREATED:20210118T081209Z
LAST-MODIFIED:20210118T081209Z
UID:28544-1617753600-1618012799@www.pharmajournalist.com
SUMMARY:Pharma: Clinical 2021
DESCRIPTION:Reuters Events’ Clinical 2021 (April 7-9) is the new home of clinical collaboration\, innovation and discovery. Join hundreds of pharma clinical innovators plus leaders from across the business\, such as real-world evidence\, medical\, and patient centricity\, alongside key regulatory bodies\, providers\, and patient representatives to form new collaborations and gain new insights through presentations\, case-studies\, workshops and collaborative working groups. \nTo know more about Pharma: Clinical 2021 please click here.
URL:https://www.pharmajournalist.com/event/pharma-clinical-2021/
LOCATION:Virtual Event
ORGANIZER;CN="Reuters Events":MAILTO:Saskia.burbach@reutersevents.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210415
DTEND;VALUE=DATE:20210417
DTSTAMP:20260515T025617
CREATED:20210226T104524Z
LAST-MODIFIED:20210226T111548Z
UID:29170-1618444800-1618617599@www.pharmajournalist.com
SUMMARY:MarketsandMarkets qPCR and dPCR Virtual Conference
DESCRIPTION:Advancing qPCR and dPCR technological developments and its applications in oncology and infectious disease diagnostics \nAs per MarketsandMarkets research analysis\, the global dPCR and qPCR is estimated to grow to USD 6\,270.9 million by 2024 at a CAGR of 8.8%. Factors such as the rising incidences of target infectious diseases and genetic disorders; continuous technological advancements in PCR technologies; increasing investments\, funds\, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However\, the high instrument costs—especially that of dPCR—and the technical limitations of PCR have restricted their greater use \n \nMarketsandMarkets are proud to host its inaugural “qPCR and dPCR Virtual Conference” which will be held on 15th – 16th April 2021. The conference will focus on the latest developments in digital and real time PCR and also\, its application in cancer diagnosis and infectious disease diagnostics \nEvent Website: https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/  \nRegistration link:  https://events.marketsandmarkets.com/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
URL:https://www.pharmajournalist.com/event/marketsandmarkets-qpcr-and-dpcr-virtual-conference/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210422
DTSTAMP:20260515T025617
CREATED:20201126T154428Z
LAST-MODIFIED:20201207T142117Z
UID:28066-1618876800-1619049599@www.pharmajournalist.com
SUMMARY:AI Driven Drug Repositioning and Repurposing Summit
DESCRIPTION:The AI Driven Drug Repositioning & Repurposing Summit will bring together 80+ leaders in repurposing and pioneers in AI and machine learning to strategize how repurposing can reach its full potential to: \n\nImprove time and cost savings of drug development\nLeverage the safety advantage in reducing development risk\nUnlock market potential advantage\nImprove return on investment for repurposed drugs\nExplore out-licensing options\n\nThis meeting aims to help pharma\, biotech and academics stay ahead of the curve in their repurposing endeavors during a period exploding with new technologies. Join cutting-edge discussions with the like of AstraZeneca\, BenevolentAI\, and Healx\, to solve ongoing technical challenges surrounding AI tools in repurposing\, understand the delicate risk-reward balance in potential repurposing opportunities and explore lessons learned from AI applications in repurposing during Covid-19. \nFeaturing 2 days of jam-packed content\, this digital summit will provide you with all the information you need to begin implementing AI tools into repurposing projects within your organization. What’s more\, our digital platform allows you to take part in live Q&A with the presenters\, take a tour of the virtual exhibition\, and even join online rooms where you can join targeted interactive discussion groups! \nTo know more about AI Driven Drug Repositioning and Repurposing Summit please click here.
URL:https://www.pharmajournalist.com/event/ai-driven-drug-repositioning-and-repurposing-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210420
DTEND;VALUE=DATE:20210423
DTSTAMP:20260515T025617
CREATED:20201224T123305Z
LAST-MODIFIED:20201224T123305Z
UID:28380-1618876800-1619135999@www.pharmajournalist.com
SUMMARY:Anti-Infectives Drug Development – Digital Summit
DESCRIPTION:Infectious diseases are one of the largest threats to global public health. The focus on the threat has never been greater\, with the COVID-19 pandemic demonstrating the critical need for a more proactive approach within governments\, biopharma\, and investment communities to overcome the pressing issues in anti-infective drug development to combat antimicrobial resistance. \nWith some now considering the field as the new ‘Wall Street darling’\, especially given the $1 billion launch of the AMR action fund\, the Digital Anti-Infectives Drug Development Summit has arrived as the most comprehensive and industry-dedicated forum that addresses the biggest challenges in the development and commercialization of anti-infective drugs. \n \nBringing together 60+ senior leaders from large pharma\, innovative biotech\, academia and investment companies\, join us this April to discuss data-driven and solution-based approaches that focus on developing high value clinical candidates\, novel modalities and effective strategies\, that address market sustainability and aim for superiority. \nWhat you can expect: \n\nReimagine anti-infective drug development to ensure economic sustainability\, with insight from Merck\, CARB-X & AlloVir\n\n\nExplore the non-traditional approaches employed to combat multi-drug resistance\, with insight from Locus Biosciences\, Peptilogics & SciBac\n\n\nAdvance the clinical superiority of anti-infectives to drive commercial success\, with insight from ContraFect & Summit Therapeutics\n\n\nTarget the unmet medical need to ensure drug development pipeline success\, with insight from BioVersys\, Entasis Therapeutics & Spero Therapeutics\n\n\nDiscover superior novel strategies to combat anti-microbial resistance\, with insight from Techulon\, MicuRX & Princeton University\n\nTo know more about Anti-Infectives Drug Development please click here.
URL:https://www.pharmajournalist.com/event/anti-infectives-drug-development-digital-summit/
LOCATION:Digital Event\, EDT
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210422
DTEND;VALUE=DATE:20210424
DTSTAMP:20260515T025617
CREATED:20210301T101134Z
LAST-MODIFIED:20210301T101134Z
UID:29204-1619049600-1619222399@www.pharmajournalist.com
SUMMARY:4th Annual MarketsandMarkets Real-World Data\, Life Sciences Analytics and Market Access Virtual Conference (Time Zone - EST)
DESCRIPTION:MarketsandMarkets is proud to announce the 4th Annual MarketsandMarkets Real-World Data\, Life Sciences Analytics and Market Access Virtual Conference to be held on 22- 23 April\, 2021. \nWhile the 3rd annual virtual conference had discussions on how the insights derived from real world data\, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators\, doctors\, and payers\, the 4th Annual conference will focus on discussion about the application of RWD/RWE across the life cycle. The event will discuss Impact of COVID-19 on the real-world generation and making sense of the Electronic Health Records data for COVID-19. \nOur aim for the 4th Annual Virtual Conference is to unite all stakeholders in a virtual room to learn how to overcome the challenges caused due to the pandemic\, efficiently and effectively generating RWE for stakeholders including payers\, patients and physicians. \nEvent Website https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/ \nRegistration link:  https://events.marketsandmarkets.com/4th-edition-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-uk-eu/register 
URL:https://www.pharmajournalist.com/event/4th-annual-marketsandmarkets-real-world-data-life-sciences-analytics-and-market-access-virtual-conference-time-zone-est/
LOCATION:Virtual Event
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210426
DTEND;VALUE=DATE:20210428
DTSTAMP:20260515T025617
CREATED:20201124T092500Z
LAST-MODIFIED:20201124T092658Z
UID:28055-1619395200-1619567999@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes East Coast 2021
DESCRIPTION:SMi are proud to announce the 8th Pre-filled Syringes East Coast virtual conference taking place on 26th and 27th April 2021. \nThe global pre-filled syringes market was valued at $4.9 billion in 2018 and with the rapid growth of the industry\, is expected to exceed $9.7 billion by 2025. With that in mind\, this event will bring together specialists within the industry to provide an exclusive insight into the sphere of regulation\, new digital technology trends\, human studies and innovative design and delivery systems within the prefilled syringe industry. \nThis comprehensive overview will help attendees understand the changing global market and the challenges faced within the industry. The upcoming conference will cover key topics driving the industry including advancing development for drug delivery devices\, regulatory updates including the FDA draft guidance on bridging studies\, connectivity and digital health for combination products and compatibility for drug delivery systems. \nThis two-day agenda offers you peer-to-peer networking with Global Product Managers\, Senior PFS Engineers\, Device Testing Managers\, Heads of Late-Stage PFS Development and many more. \nWe look forward to welcoming you to the conference in April 2021. \n \nWho should attend: \n\nDrug-delivery developers\nMedical Device Engineers\nPrimary Packaging material designers\nSecondary packagers\nSmart device developers\nTraining device developers\nDevice-safety solution providers\nDrug developers\n\nTo register or for more information visit: www.pfsamericas.com/pjwl \nBenefit of attending:  \nPre-Filled Syringes East Coast will explore the latest industry updates on pre-filled syringes exploring considerations for platforms and integrated development. Gain insights into how the industry has overcome challenges of the pandemic with case studies on human factors studies and the acceleration towards connectivity for delivery devices. Hear from leading industry and regulatory experts on life cycle management\, guidance on bridging studies and biocompatibility considerations. \nThe SMi Virtual Conference Platform will deliver the following benefits: \n\nLive and On Demand speaker content: Get access to the latest strategies and case studies from your marketplace online!\nNetwork with all the event attendees: Connect\, see who’s attending\, chat and share contact details with all online delegates\, speakers and sponsors\nExhibit a Virtual Booth: You can pack your customized booth full of documents\, videos and even show who is manning the booth during the event and hosting meetings\nHost & Join Meetings & Socials: Join preferred speaking sessions\, host you own meetings and even a virtual Networking social\, with in built Zoom functionality\n\nAdditional Contact Info:\nT: +44 (0)20 7827 6088\nE: hsidhu@smi-online.co.uk\nTwitter: @SMiPharm #Smipfsusa\nLinkedIn: follow our company page – search ‘SMi Pharma’
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-east-coast-2021/
LOCATION:Virtual conference: Online access only
ORGANIZER;CN="SMi Group":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210426
DTEND;VALUE=DATE:20210429
DTSTAMP:20260515T025617
CREATED:20210208T084959Z
LAST-MODIFIED:20210208T084959Z
UID:28858-1619395200-1619654399@www.pharmajournalist.com
SUMMARY:Strategic Operational Excellence in Life Sciences
DESCRIPTION:Strategic Operational Excellence in Life Sciences is a brand new forum\, designed for and by strategic operations and operational excellence leaders in the Life Sciences\, with a vision to create a holistic\, enterprise-wide dialogue around business excellence innovation\, to ultimately redefine operational excellence as a competitive advantage for the modern scientific organization. \nIt will shine a light on the boldest operational excellence leaders from the most admired biopharma and medical devices businesses\, sharing their stories of process excellence innovation\, nurturing cultures of continuous improvement and re-examining supply chain operations during and beyond Covid-19. \nTo know more about Strategic Operational Excellence in Life Sciences please click here.
URL:https://www.pharmajournalist.com/event/strategic-operational-excellence-in-life-sciences/
LOCATION:Exclusive Virtual Conference
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T025617
CREATED:20210115T080512Z
LAST-MODIFIED:20210115T080512Z
UID:28488-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Interstitial Lung Disease Drug Development Summit
DESCRIPTION:Network with over 50 other industry pioneers including Ionis Pharmaceuticals\, Genentech\, Vicore and AnaMar to hear first-hand how the latest scientific research is innovating and upgrading ILD therapeutics at this trailblazing new meeting. \n \nThe 1st Interstitial Lung Disease Drug Development Summit is a ground-breaking new conference dedicated to helping you drive forward the development of effective therapies for chronic fibrosing ILDs and achieve success in anti-fibrotic drug development beyond IPF. \nVisit our website to download our event guide.
URL:https://www.pharmajournalist.com/event/interstitial-lung-disease-drug-development-summit/
LOCATION:Virtual Conference
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T025617
CREATED:20210118T174336Z
LAST-MODIFIED:20210118T174336Z
UID:28564-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:3rd Neuroimmunology Drug Development Summit
DESCRIPTION:As diverse programs are advancing towards the clinic\, there is a dire need to tackle the many translational challenges neuro-immunologists are facing to develop clinically effective neuroimmunology targeted therapeutics. \n \nBuilding on the success of last year’s meeting\, the 3rd Neuroimmunology Drug Development Summit will uncover how leading companies in this emerging field are discovering immune-modulating targets and deploying immuno-neurology across clinical case studies. As we gather the best minds in this infant field we will put a spotlight on the latest key learnings across microglia\, astrocytes\, STING\, TREM2 and more to help pave the way to translating key technological and mechanistic insights towards the clinic. \nJoin this intimate\, industry led forum to not only learn from those pioneering the field\, but to network and build meaningful partnerships with 80+ neuroimmunology drug development experts. \nTo find out more and view the 2021 speaker line-up\, download the 2021 event guide.
URL:https://www.pharmajournalist.com/event/3rd-neuroimmunology-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210427
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T025617
CREATED:20210121T100547Z
LAST-MODIFIED:20210121T100547Z
UID:28587-1619481600-1619740799@www.pharmajournalist.com
SUMMARY:Mitochondria-Targeted Drug Development Digital Summit
DESCRIPTION:The Mitochondria-Targeted Drug Development Digital Summit is the only industry-led meeting focused on end-to-end mitochondria-targeting. Explore success stories from leading experts overcoming common challenges whilst exploring what’s next to help you accelerate your pipeline into the clinic. \nWith 20+ hours of content\, 2 interactive workshops and over 5 hours of networking with key industry leaders from Larimar Therapeutics\, Minovia Therapeutics\, Mitokinin and many more\, this comprehensive forum will completely focus on mitochondria-targeting drug development and the current challenges and opportunities in the field. \n \nMake this your 2021 must-attend meeting and network with 80+ senior CSOs\, CEOs\, research scientists\, academics and investors committed to targeting mitochondria to tackle challenges with Mitochondrial & Age-related Diseases. \nIn this focused summit\, you’ll learn from the field’s pioneers who’ll be sharing their experience in: \n\nExploring the role of mitochondrial dysfunction in age-related diseases & rare genetic mitochondrial diseases\nExamining early discovery and research findings\nEvaluating preclinical drug development and studies\nDiscovering the patient perspective to aid mitochondria-targeted drug development\nAssessing clinical development and showcasing current trials\nLessons learned from clinical trial design and how design can be improved to mitigate common challenges\nRealizing the use of gene therapy\, editing technology and innovation\n\nTo know more about Mitochondria-Targeted Drug Development Digital Summit please click here.
URL:https://www.pharmajournalist.com/event/mitochondria-targeted-drug-development-digital-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210428
DTEND;VALUE=DATE:20210430
DTSTAMP:20260515T025617
CREATED:20210122T095626Z
LAST-MODIFIED:20210122T095626Z
UID:28611-1619568000-1619740799@www.pharmajournalist.com
SUMMARY:SMi’s 4th Annual Pharmaceutical Microbiology East Coast Conference
DESCRIPTION:Sponsor: Microcoat \nChaired by Lynne Ensor\, Vice President\, RCS Head of Global Compliance\, Parexel \nExploring Agile Contamination Control Strategy \nBiologic products require diligent microbial control because of their complex and sometimes growth-promoting manufacturing processes\, and high-risk patient populations. The increase in complexity of pharmaceutical products\, rise in development of biologics and increasingly stringent regulations for biologics are some of the factors that are driving the growth of the pharmaceutical microbiology market for biopharmaceutical products. \n \nSMi Group invite all microbiologists to join the virtual conference to discuss Contamination Control Strategies\, Effective Environmental Monitoring\, and the newest schools of thought in personnel operation. Leaders in regulation and compliance will provide expert viewpoints on how to implement and interpret the regulation\, in addition\,  Annex 1 will be assessed and debated. \nThe industrial microbiology market is made up of equipment and systems. The equipment comprises the filtration pumps & systems\, microbial detection systems\, air monitoring systems\, incubators & culture apparatus\, etc. This equipment is used in series of microbiological tests by the industry\, where they play a vital role as they provide the ease in the testing procedure. In industrial microbiology test types\, microbial tests are carried out to study the total viable count of the specific organism present in a solution. \nThe Microbiological industry continues to swell and is set to reach a Record CAGR of 7.1% Rise in Growth by 2024. The Global Clinical Microbiology Market is expected to reach USD 4.95 billion by 2023. \nEvent Hashtag: #SMiPharmaMicroEC \nHighlights for 2021: \n\nEXPLORE the latest advancements in robust risk-based disinfection strategies for effective cleaning and microbe elimination\nINVESTIGATE the extensive and complex regulatory landscape alongside the regulators\nDELVE into recent case studies delivered by experts in microbial monitoring and contamination control programs\nATTAIN expert tuition at the post-conference workshops in new quality risk management tools for contamination control and the latest revisions in the USP\nVIRTUAL CONFERENCE benefits include: virtual exhibition booths packed with information\, networking features to discuss and share contact details with other attendees\, and virtual meetings and networking socials\n\n2 Interactive Pre-Conference Workshops on April 27\, 2021 \nWorkshop A: USP Microbiology 2021 – Keeping Up with Standards \nLed by: Donald Singer\, Microbiology Expert Committee Chair\, US Pharmacopoeia \nWorkshop B: Quality Risk Management Tools for Contamination Control \nLed by: Cheryl Essex\, Head of Microbiological Control for Biologics\, Sanofi and Jon Williams\, Global Proactive Risk Manager\, Sanofi \nView the full agenda: www.microbiologyeastcoast.com  \nWHO SHOULD ATTEND? \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist\, Drug Substance External Manufacturer\, QC Scientists\, Heads of Quality\, Business Development Manager\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist
URL:https://www.pharmajournalist.com/event/smis-4th-annual-pharmaceutical-microbiology-east-coast-conference/
LOCATION:Online Access Only
ORGANIZER;CN="SMi Group":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
END:VCALENDAR